Estados financieros detallados de Allogene Therapeutics, Inc. (ALLO): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto -7.0%, margen operativo -38.9%, margen neto -35.7%.
Al precio actual de $1.69, ALLO presenta beneficios negativos (P/E no significativo) y un ROE del -50.04%. La capitalización bursátil es de $583M.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | $114.1M | $156000 | $95000 | $22000 | 0 |
| Coste de Ventas | 0 | 0 | $5.0M | $11.5M | 0 | $14.3M | 0 | 0 | $12.4M |
| Beneficio Bruto | 0 | -$1.5M | -$5.0M | -$11.5M | $114.1M | -$14.1M | $95000 | $22000 | -$12.4M |
| I+D | 0 | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | $150.2M |
| Generales y Administrativos | $2000 | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | $56.8M |
| Gastos Operativos | $2000 | $192.8M | $202.0M | $246.7M | $294.3M | $321.4M | $327.8M | $273.2M | $194.6M |
| Beneficio Operativo | -$2000 | -$192.8M | -$202.0M | -$258.2M | -$180.2M | -$335.5M | -$327.7M | -$273.2M | -$206.9M |
| EBITDA | $22000 | -$206.8M | -$179.9M | -$238.7M | -$171.6M | -$326.1M | -$313.1M | -$243.3M | -$177.5M |
| Gastos por Intereses | 0 | $3.4M | 0 | 0 | 0 | 0 | 0 | $181000 | $1.1M |
| Beneficio Antes de Impuestos | -$24000 | -$211.6M | -$184.9M | -$250.2M | -$182.1M | -$340.4M | -$327.3M | -$257.1M | -$190.9M |
| Impuestos | -$24000 | -$117000 | -$331000 | 0 | 0 | 0 | 0 | $443000 | 0 |
| Beneficio Neto | -$2000 | -$211.5M | -$184.6M | -$250.2M | -$182.1M | -$340.4M | -$327.3M | -$257.6M | -$190.9M |
| BPA | $-0.00 | $-2.36 | $-1.83 | $-2.08 | $-1.34 | $-2.38 | $-2.09 | $-1.32 | $-0.87 |
| BPA Diluido | $-0.00 | $-2.36 | $-1.83 | $-2.08 | $-1.34 | $-2.38 | $-2.09 | $-1.32 | $-0.87 |
| Acciones en Circulación (Diluidas) | $44.0M | $89.7M | $101.1M | $120.4M | $135.8M | $143.1M | $156.9M | $194.8M | $220.6M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | $4.6M |
| Beneficio Bruto | -$31.2M | -$3.1M | -$2.9M | $4.6M |
| Beneficio Operativo | -$44.9M | -$42.4M | -$46.1M | -$46.9M |
| EBITDA | -$38.0M | -$35.4M | -$39.4M | -$39.7M |
| Beneficio Neto | -$41.4M | -$38.8M | -$42.6M | -$42.7M |
| BPA | $-0.19 | $-0.17 | $-0.18 | $-0.13 |
| BPA Diluido | $-0.19 | $-0.17 | $-0.18 | $-0.13 |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | 0 | $721.4M | $175.1M | $183.4M | $173.3M | $61.9M | $83.2M | $75.2M | $51.7M |
| Inversiones a Corto | 0 | 0 | $355.4M | $644.6M | $284.0M | $455.4M | $365.5M | $217.3M | $198.5M |
| Cuentas por Cobrar | 0 | $3.1M | $2.4M | 0 | 0 | 0 | $1.7M | $1.9M | $1.5M |
| Inventario | 0 | -$262.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | 0 | $468.0M | $544.6M | $845.1M | $471.3M | $528.8M | $459.1M | $303.4M | $257.7M |
| Inmovilizado Material | 0 | $41.6M | $100.9M | $160.1M | $181.0M | $196.4M | $163.2M | $131.3M | $112.7M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | $754000 | $151000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | 0 | $773.9M | $717.8M | $1.23B | $1.05B | $821.6M | $642.8M | $548.7M | $415.9M |
| Cuentas por Pagar | 0 | $12.3M | $9.2M | $10.4M | $10.3M | $13.9M | $5.9M | $5.4M | $4.3M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $2000 | $29.5M | $33.1M | $94.3M | $47.9M | $53.7M | $37.1M | $35.5M | $32.5M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $2000 | $70.7M | $88.8M | $148.2M | $125.6M | $154.7M | $130.6M | $126.5M | $123.4M |
| Reservas | -$23000 | -$211.5M | -$396.1M | -$646.3M | -$894.6M | -$1.23B | -$1.56B | -$1.82B | -$2.01B |
| Patrimonio Neto | -$2000 | $703.2M | $629.0M | $1.08B | $925.2M | $666.9M | $512.2M | $422.2M | $292.5M |
| Deuda Total | 0 | $34.5M | $53.0M | $53.8M | $73.1M | $101.1M | $95.1M | $90.8M | $83.3M |
| Deuda Neta | 0 | -$686.9M | -$477.5M | -$774.1M | -$384.2M | -$416.2M | -$353.6M | -$201.7M | -$167.0M |
| Capital Circulante | -$2000 | $438.5M | $511.5M | $750.8M | $423.4M | $475.1M | $422.0M | $267.9M | $225.2M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $37.8M | $51.7M | $30.3M | $38.6M |
| Activos Totales | $439.8M | $415.9M | $396.0M | $550.1M |
| Pasivos Totales | $124.4M | $123.4M | $117.1M | $113.9M |
| Patrimonio Neto | $315.3M | $292.5M | $278.9M | $436.2M |
| Deuda Total | $85.1M | $83.3M | $81.1M | $70.4M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$24000 | -$211.5M | -$184.6M | -$250.2M | -$257.0M | -$332.6M | -$327.3M | -$257.6M | -$190.9M |
| Amortizaciones | 0 | $1.5M | $5.0M | $7.6M | $10.5M | $14.3M | $14.2M | $13.6M | $12.4M |
| Compensación en Acciones | 0 | $18.6M | $46.1M | $65.3M | $80.8M | $83.6M | $66.0M | $51.7M | $37.6M |
| Cambio en Capital Circulante | $24000 | $12.1M | -$6.9M | $53.9M | -$32.1M | $3.7M | -$15.3M | -$24.8M | -$10.9M |
| Flujo de Caja Operativo | 0 | -$44.7M | -$137.3M | -$115.1M | -$184.8M | -$220.5M | -$237.7M | -$200.3M | -$149.2M |
| Inversiones (CapEx) | 0 | -$3.2M | -$50.8M | -$66.0M | -$21.4M | -$5.2M | -$1.5M | -$694000 | -$386000 |
| Adquisiciones | 0 | 0 | -$5.1M | $439.2M | -$17.7M | -$111.3M | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | 0 | -$47.9M | -$188.1M | -$181.1M | -$206.3M | -$225.7M | -$239.2M | -$201.0M | -$149.6M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$29.7M | -$27.6M | -$12.9M | -$32.0M |
| Inversiones (CapEx) | -$243000 | 0 | -$9000 | -$150000 |
| Flujo de Caja Libre | -$29.9M | -$27.6M | -$12.9M | -$32.1M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $8.7M | $8.1M | $8.3M | $12.4M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | -99.9% | -39.1% | -76.8% | -100.0% |
| Crecimiento Beneficio Neto (anual) | | -10575150.0% | +12.7% | -35.6% | +27.2% | -87.0% | +3.9% | +21.3% | +25.9% |
| Crecimiento BPA (anual) | | -5193230.5% | +22.5% | -13.7% | +35.6% | -77.6% | +12.2% | +36.8% | +34.1% |
| Cambio en Acciones (anual) | | +103.8% | +12.7% | +19.1% | +12.8% | +5.4% | +9.6% | +24.1% | +13.2% |
| Crecimiento FCF (anual) | | | -292.9% | +3.8% | -13.9% | -9.4% | -6.0% | +16.0% | +25.6% |
| Margen Bruto | | | | | 100.0% | -9063.5% | 100.0% | 100.0% | |
| Margen Operativo | | | | | -157.9% | -215087.2% | -344986.3% | -1241813.6% | |
| Margen EBITDA | | | | | -150.4% | -209050.6% | -329543.2% | -1106031.8% | |
| Margen Neto | | | | | -159.6% | -218214.1% | -344489.5% | -1170863.6% | |
| Margen FCF | | | | | -180.8% | -144685.9% | -251841.1% | -913609.1% | |
| Tasa Impositiva Efectiva | 100.0% | 0.1% | 0.2% | -0.0% | -0.0% | -0.0% | -0.0% | -0.2% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $0.00 | $-0.53 | $-1.86 | $-1.50 | $-1.52 | $-1.58 | $-1.52 | $-1.03 | $-0.68 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $44.0M | $89.7M | $101.1M | $120.4M | $135.8M | $143.1M | $156.9M | $194.8M | $220.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -50.04% |
| Rentabilidad sobre capital invertido | -34.79% |
| Rentabilidad sobre activos | -30.08% |
| Margen bruto | -699.35% |
| Margen operativo | -3886.14% |
| Margen neto | -3566.68% |
Salud financiera
| Deuda / Patrimonio | 0.16 |
| Ratio corriente | 10.72 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -550140.95 | -11.41 | -14.20 | -12.13 | -11.13 | -2.64 | -1.54 | -1.61 | -1.57 |
| P/VC | -550140.92 | 3.43 | 4.17 | 2.81 | 2.19 | 1.35 | 0.98 | 0.98 | 1.03 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 17.76 | 5771.76 | 5302.65 | 18861.34 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | -9063.5% | 100.0% | 100.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -157.9% | -215087.2% | -344986.3% | -1241813.6% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -159.6% | -218214.1% | -344489.5% | -1170863.6% | 0.0% |